- Review
33 Pages
The increasing incidence of fungal infections caused by Candida albicans and the multidrug-resistant emerging pathogen Candidozyma auris (formerly Candida auris) represents a major global healthcare challenge. Current antifungal therapies are limited by toxicity, drug–drug interactions, rapid resistance emergence, and poor efficacy against fungal biofilms, highlighting the urgent need for novel antifungal agents with new mechanisms of action. In this context, marine ecosystems have emerged as an exceptional source of structurally diverse natural products with promising pharmacological properties. This review summarizes recent advances in marine-derived compounds exhibiting antifungal activity against C. albicans and C. auris. The available evidence is organized according to major chemical classes, including polyketides, alkaloids, terpenoids and meroterpenoids, and miscellaneous marine metabolites. Particular emphasis is placed on antifungal potency, mechanisms of action, anti-biofilm and anti-virulence activities, synergistic interactions with conventional antifungal drugs, and reported structure–activity relationships. Several compounds demonstrated potent direct antifungal activity, while others showed mainly antibiofilm, anti-virulence, synergistic, or resistance-modifying effects despite having limited direct growth-inhibitory activity. Although many promising candidates remain at the preclinical stage, current evidence suggests that marine natural products have significant potential as scaffolds for discovering and developing next-generation antifungal therapeutics. Continued interdisciplinary research integrating natural product chemistry, medicinal chemistry, pharmacology, and translational studies will be essential for transforming these compounds into clinically useful antifungal drugs.
Appl. Biosci.
3 October 2026



![PRISMA flow diagram summarizing the identification, screening, eligibility assessment, inclusion and the exclusion of studies in the systematic review. Source of the template for PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only [25].](https://mdpi-res.com/cdn-cgi/image/width=281%2Cheight=192/https://mdpi-res.com/applbiosci/applbiosci-05-00090/article_deploy/html/images/applbiosci-05-00090-g001-550.jpg)



![(A) Effect of frequency and temperature on the electric energy dissipated in the suspension of either human RBCs or their isolated plasma membranes. The energy loss is expressed by the imaginary capacitance, C″ (pF), of suspension plotted against the frequency of the electric field, f (MHz). The straight line reflects the conduction loss in the suspension, while the shadowed area represents the dielectric loss curve, Cd″ (pF), of the plasma membranes of RBCs. The temperature and hematocrit were 25 °C and 45%, respectively. (B) Effect of the temperature on the dielectric loss curve, Cd″ (pF) against f (MHz), for suspensions of either human RBCs or their isolated plasma membranes. The temperature of suspension was 41 °C (□), 47 °C (Δ) and 53 °C (●). The temperature-corrected differential dielectric loss curve (○) of the spectrin network at Ts, ΔCd″ (pF) against f (MHz), is noted by the arrow. Adapted from Ref. [1]. For further details, see the text.](https://mdpi-res.com/cdn-cgi/image/width=281%2Cheight=192/https://mdpi-res.com/applbiosci/applbiosci-05-00028/article_deploy/html/images/applbiosci-05-00028-g001-550.jpg)

